Acadia Pharmaceuticals
ACAD
231 hedge funds and large institutions have $5.28B invested in Acadia Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 74 increasing their positions, 66 reducing their positions, and 27 closing their positions.
130% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 27
51% more call options, than puts
Call options by funds: $79.5M | Put options by funds: $52.7M
43% more capital invested
Capital invested by funds: $3.69B → $5.28B (+$1.59B)
18% more funds holding
Funds holding: 196 → 231 (+35)
12% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 66
1.45% more ownership
Funds ownership: 95.87% → 97.32% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$80M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$47.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$34M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.5M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$20.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$51.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$36.1M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$20M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$13.3M |
| 5 |
Goldman Sachs
New York
|
-$11.5M |
ACAD Hedge Fund Activity: Q3 2019 in Review
231 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2019, worth a combined $5.28B — up 43% from $3.69B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new ACAD positions and 27 closed out — a net gain of 35 holders — while 74 added to existing stakes and 66 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $80M. The largest seller was First Trust Advisors, cutting an estimated $51.2M.
- 231 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2019, up from 196 in Q2 2019.
- Funds reported $5.28B of Acadia Pharmaceuticals stock for Q3 2019, up 43% quarter-over-quarter.
- 62 funds opened new Acadia Pharmaceuticals positions in Q3 2019 and 27 closed out, a net change of +35 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2019 was T. Rowe Price Associates, an estimated $80M added.
- The largest Acadia Pharmaceuticals seller in Q3 2019 was First Trust Advisors, an estimated $51.2M sold.
Based on aggregated 13F filings for Q3 2019.